Skip to main content

Search

Show all results for

Home

Person

David Viertl

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (4)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release

Natalia Gasilova, Jean-Manuel Segura, David Viertl

Template-directed methods are emerging as some of the most effective means to conjugate payloads at selective sites of monoclonal antibodies (mAbs). We have previously reported a method based on an engineered Fc-III reactive peptide to conjugate a radionuc ...

Royal Soc Chemistry2023

68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging. Preclinical investigation and dosimetry

Carole Poitry-Yamate, Christian Rüegg, Serge Baechler, David Viertl

To visualize neovasculature and/or tumour integrin αvβ3 we selected the binding moiety Arg-Gly-Asp-D-Tyr-Lys (RGDyK) coupled to NODAGA for labeling with 68Ga. ...

Schattauer2011

Increase of [F-18]FLT Tumor Uptake In Vivo Mediated by FdUrd: Toward Improving Cell Proliferation Positron Emission Tomography

Rolf Gruetter, Bernard Lanz, Carole Poitry-Yamate, David Viertl, Hans-Anton Lehr

3'-deoxy-3'-[F-18]fluorothymidine ([F-18]FLT), a cell proliferation positron emission tomography (PET) tracer, has been shown in numerous tumors to be more specific than 2-deoxy-2-[F-18]fluoro-d-glucose ([F-18]FDG) but less sensitive. We studied the capaci ...

Elsevier2011